Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. Issue 1 (10th September 2020)

• Record Type: Journal Article
• Authors: McClure, Tess; Cui, Wanyuan; Asadi, Khashayar; John, Thomas; Testro, Adam
• Is Part Of: BMJ open gastroenterology. Volume 7:Issue 1(2020)
• Publication Date: 2020-09-10
• Subjects: cholestatic liver diseases -- cancer immunobiology -- liver function test -- drug toxicity -- autoimmune biliary disease; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/bmjgast-2020-000487
• Languages: English
• ISSNs: 2054-4774

Abstract

Abstract : Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.